Reactions Weekly

, Volume 1733, Issue 1, pp 188–188 | Cite as

Immune checkpoint inhibitors

Various immune-related adverse events: 34 case reports
Case report
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

In a retrospective study conducted from 1st September 2014 to 30th March 2017, consisting of 36 patients, 34 patients (including one female) [not allages and sexes stated] were described, who developed rheumatic immune related adverse events consisting of flare of pre-existing rheumatic condition, arthritis, myositis, myocarditis, polymyalgia rheumatica or fascitis, and non-rheumatic immune related adverse events consisting of colitis, acute interstitial nephritis, thyrotoxicosis, pneumonitis, thyroiditis, vitiligo, pruritus, rash, bilateral uveitis, bullous skin lesions, hypophysitis, pancreatitis, elevated levels of amylase and lipase, hepatitis or type 1 diabetes mellitus following treatment with pembrolizumab, nivolumab, ipilimumab, carboplatin, talimogene laherparepvec or...


  1. Mitchell EL, et al. Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. European Journal of Cancer 105: 88-102, Dec 2018. Available from: URL: - Australia

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations